Live feed07:00:00·45dPRReleaseDecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% RiskCSTL· Castle Biosciences Inc.Health CareOriginal source
